KR101004662B1 - 에너지 항상성에 관여하는 신규한 펩티드 - Google Patents

에너지 항상성에 관여하는 신규한 펩티드 Download PDF

Info

Publication number
KR101004662B1
KR101004662B1 KR1020087005454A KR20087005454A KR101004662B1 KR 101004662 B1 KR101004662 B1 KR 101004662B1 KR 1020087005454 A KR1020087005454 A KR 1020087005454A KR 20087005454 A KR20087005454 A KR 20087005454A KR 101004662 B1 KR101004662 B1 KR 101004662B1
Authority
KR
South Korea
Prior art keywords
swirl
mice
seq
delete delete
obesity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020087005454A
Other languages
English (en)
Korean (ko)
Other versions
KR20080042866A (ko
Inventor
앤드류 에이. 버틀러
제임스 엘. 트레바스키스
Original Assignee
더 보드 오브 수퍼바이저스 오브 루이지애나 스테이트 유니버시티 앤드 애그리컬춰럴 앤드 미케니칼 칼리지
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 보드 오브 수퍼바이저스 오브 루이지애나 스테이트 유니버시티 앤드 애그리컬춰럴 앤드 미케니칼 칼리지 filed Critical 더 보드 오브 수퍼바이저스 오브 루이지애나 스테이트 유니버시티 앤드 애그리컬춰럴 앤드 미케니칼 칼리지
Publication of KR20080042866A publication Critical patent/KR20080042866A/ko
Application granted granted Critical
Publication of KR101004662B1 publication Critical patent/KR101004662B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
KR1020087005454A 2005-08-05 2006-08-07 에너지 항상성에 관여하는 신규한 펩티드 Expired - Fee Related KR101004662B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70594005P 2005-08-05 2005-08-05
US60/705,940 2005-08-05

Publications (2)

Publication Number Publication Date
KR20080042866A KR20080042866A (ko) 2008-05-15
KR101004662B1 true KR101004662B1 (ko) 2011-01-03

Family

ID=37727967

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020087005454A Expired - Fee Related KR101004662B1 (ko) 2005-08-05 2006-08-07 에너지 항상성에 관여하는 신규한 펩티드

Country Status (10)

Country Link
US (4) US20090253619A1 (enExample)
EP (1) EP1928487A4 (enExample)
JP (1) JP2009502208A (enExample)
KR (1) KR101004662B1 (enExample)
CN (1) CN101505786A (enExample)
AU (2) AU2006278406B2 (enExample)
CA (1) CA2618047C (enExample)
IL (2) IL189065A (enExample)
RU (2) RU2409590C2 (enExample)
WO (1) WO2007019426A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011140296A1 (en) 2010-05-05 2011-11-10 Infinity Pharmaceuticals Triazoles as inhibitors of fatty acid synthase
EP3159331A1 (en) 2010-05-05 2017-04-26 Infinity Pharmaceuticals, Inc. Tetrazolones as inhibitors of fatty acid synthase
US11246912B2 (en) * 2017-08-30 2022-02-15 Hadasit Medical Research Services & Development Ltd. Methods for treating and diagnosing metastatic liver cancer
US11969460B2 (en) * 2018-06-08 2024-04-30 Saint Louis University Methods and compositions for treating decreased cognitive ability
CN110028570A (zh) * 2018-10-31 2019-07-19 华中科技大学 一种肌肉素的表达方法及其在代谢疾病中的应用
WO2024263938A2 (en) * 2023-06-23 2024-12-26 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Using enho gene therapy to treat cardiometabolic disease

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030096951A1 (en) 1998-08-14 2003-05-22 Kenneth Jacobs Secreted proteins and polynucleotides encoding them

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2078345C1 (ru) * 1992-04-03 1997-04-27 Аникеева Светлана Петровна Способ получения сывороточного белкового препарата, влияющего на активность окислительно-энергетического обмена
WO2000009552A1 (en) * 1998-08-14 2000-02-24 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
US6783969B1 (en) * 2001-03-05 2004-08-31 Nuvelo, Inc. Cathepsin V-like polypeptides

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030096951A1 (en) 1998-08-14 2003-05-22 Kenneth Jacobs Secreted proteins and polynucleotides encoding them

Also Published As

Publication number Publication date
AU2006278406A1 (en) 2007-02-15
CA2618047C (en) 2015-04-14
US20160102126A1 (en) 2016-04-14
IL189065A (en) 2012-10-31
WO2007019426A2 (en) 2007-02-15
RU2010119559A (ru) 2011-11-20
AU2010202600A1 (en) 2010-07-15
US20130231280A1 (en) 2013-09-05
EP1928487A4 (en) 2009-11-04
US8518892B2 (en) 2013-08-27
CA2618047A1 (en) 2007-02-15
AU2006278406B2 (en) 2010-03-25
WO2007019426A3 (en) 2009-04-23
CN101505786A (zh) 2009-08-12
IL189065A0 (en) 2008-08-07
IL207764A0 (en) 2010-12-30
KR20080042866A (ko) 2008-05-15
RU2008108509A (ru) 2009-09-10
AU2010202600B2 (en) 2012-07-19
US20090253619A1 (en) 2009-10-08
JP2009502208A (ja) 2009-01-29
US20100299769A1 (en) 2010-11-25
RU2409590C2 (ru) 2011-01-20
EP1928487A2 (en) 2008-06-11

Similar Documents

Publication Publication Date Title
US6777388B1 (en) Leptin-related peptides
Frühbeck et al. Control of body weight: a physiologic and transgenic perspective
US7790683B2 (en) Leptin-related peptides
US20160102126A1 (en) Novel Peptides Involved in Energy Homeostasis
Shimizu et al. The brain–adipose axis: A review of involvement of molecules
WO2004039832A2 (en) Leptin-related peptides
JP2003520015A (ja) 体重およびそれに関連する状態を調節する組成物および方法
US20090104203A1 (en) Compositions and Methods for Regulating Osteoclast Differentiation, Activation and Bone Resorption
US6689938B2 (en) Method for treatment of insulin resistance in obesity and diabetes
HK1135608A (en) A novel peptide involved in energy homeostasis
EP1736171A1 (en) Antiobesity drug
Ohkubo Recent progress in avian leptin research
Stewart Biochemical and Physiological Characterization of Secreted Proteins Regulating Whole-body Energy Homeostasis
Ono et al. sererer denser kkk kkkk
Patel A role for CEACAM2 in insulin homeostasis and action
Rajala Functional characterization of resistin, a novel adipokine
EP2010564A2 (en) The homeobox transcription factor bsx and uses thereof for treating diseases, in particular obesity

Legal Events

Date Code Title Description
A201 Request for examination
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20131219

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20141219

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20151223

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20151223